Cube&Company Co., Ltd. Overview
| Field | Detail | Source |
|---|---|---|
| Current legal name | 주식회사 더테크놀로지 / The Technology Co., Ltd. | KIND quarterly report (Q3 FY2025), Edaily 29 Mar 2024 |
| Name requested in brief | Cube&Company Co., Ltd. (큐브앤컴퍼니), used 24 Oct 2019 – Sep 2021 | Hankyung / Edaily / Newspim, 24 Oct 2019 |
| Former names (chronological) | Korea Fermentation Co. (한국발효기㈜) → Co-Biotech (코바이오텍㈜, Apr 2000) → Pharmswell Bio (팜스웰바이오, May 2008) → Cube&Company (Oct 2019) → Hanju Chemical & Holdings (한주케미칼앤홀딩스, Sep 2021) → Hanchang Biotech (한창바이오텍, Nov 2021) → Exergy21 (엑서지21, Sep/Oct 2022) → The Technology (Mar 2024) | KIND Q3 FY2025 report; Incruit history; Digital Today 14 Mar 2024 |
| Founding / incorporation | Converted to a corporation as Korea Fermentation Co. in April 1987 (registered incorporation date shown as 9 May 1987). The accounting acquirer in the 2008 merger, Pharmswell Co., was founded in 1999 | Incruit company history; Medical Times 8 May 2008 |
| Incorporation jurisdiction | Republic of Korea | Filings (via press) |
| Headquarters | Not confirmed in a current filing. The head office moved to a knowledge-industry centre in Wonju Innovation City, Gangwon Province, in May 2018. Simply Wall St lists Seoul. The March 2024 AGM was held at a shared-office venue in Gangnam-gu, Seoul | Etoday 4 Jun 2018; Simply Wall St; Digital Today 14 Mar 2024 |
| Stock exchange (historical) | KOSDAQ (Korea Exchange), listed October 2001; delisted 10 August 2026 | Findata (DART extract); Digital Today 28 Jul 2026 |
| Current trading venue | K-OTC (Korea Financial Investment Association), Delisted Company Section, from 30 Sep 2026 for up to 6 months | SBS Biz 28 Sep 2026 |
| Ticker | 043090 (formerly 043090.KQ) | KRX |
| ISIN | KR7043090000 (derived using the standard KRX ISIN structure and check digit; not confirmed against a filing) | Analyst derivation |
| CUSIP | Not applicable / not publicly disclosed | — |
| Fiscal year end | 31 December | ValueLine Korea |
| Employees | 34 (Google Finance, undated); 21 (Simply Wall St, 2025); 37 (Incruit, 2025 data). Official headcount trend not publicly disclosed | As listed |
| Auditor | Not publicly disclosed in the sources reviewed. In May 2026 the Securities & Futures Commission imposed a 3-year designated-auditor regime | Asia Economy 6 May 2026 |
| Shares outstanding | About 4.14 million (after a 2026 share consolidation); 12,418,275 as of Sep 2025 | ValueLine (Q1 FY2026 update); Digital Today 3 Sep 2025 |
| Market capitalisation | About KRW 0.7bn at the last KOSDAQ liquidation-trading price (KRW 171, 7 Aug 2026). About KRW 0.43bn at the K-OTC reference price of KRW 103 (derived: 103 × ~4.14M shares) | StockHub; analyst derivation |
| Largest shareholder | PNS Industry Fund (피엔에스인더스트리펀드) and related parties, 13.42% (Sep 2025). From Nov 2025 the fund's controlling contributors are DB Investment and Fastround | Digital Today 3 Sep 2025; Dealsite 5 Nov 2025 |
| CEO | Park Sung-min (박성민), per press reports in Sep 2026 | Sateconomy 28 Sep 2026 |
| Website | pharmswell.com (legacy domain; it still shows the Cube&Company name). A later domain, exergy21.net, was used for merger notices | Company site; KIND merger notice |
The Technology Co., Ltd. began as a Korean fermentation company and in 2008 merged with synthetic-API maker Pharmswell. For most of its history it produced generic active pharmaceutical ingredients. Since 2019, a sequence of short-tenure controlling shareholders has used the listed shell to fund a series of unrelated diversifications: in-vitro diagnostics, fire-suppression holdings, real-estate project management, air-source heat pumps, food-waste processor distribution, second-hand IT infrastructure, mobile-game publishing and anti-drone technology. Each was accompanied by a name change and by convertible-bond or rights-issue financing.
Revenue never scaled. It peaked at KRW 16.8bn in FY2023 against an operating loss of KRW 16.0bn. Regulators later found that FY2021–FY2022 revenue had been partly fabricated. After failing KOSDAQ's revenue and quality thresholds, the company was delisted in August 2026.
Today it is best characterised as a loss-making, sub-scale domestic distributor and holding vehicle, trading over the counter, with going-concern, governance and legal risks that dominate any operating thesis.
Company's own description (paraphrased from the latest periodic report, as summarised by ValueLine Korea, Q1 FY2026 update)
The company describes itself as founded in 1987 and listed on KOSDAQ in 2001, with pharmaceutical raw-material (API) manufacturing and sales as its historical core. It says it built capability in API synthesis and production. To lift revenue and create new profit sources, it is diversifying into four reporting areas:
Distribution: it entered the food-waste processor market, framed as an ESG initiative.
Network equipment: sale of network equipment.
Games: mobile-game launches and direct publishing through alliances with game publishers.
Other: pharmaceuticals, the Exergy heat-pump business and miscellaneous activities.
Independent characterisation
On the evidence available, the business is a multi-line trading and distribution company with a residual pharmaceutical franchise, not a technology company in any substantive sense.
Revenue model: almost entirely product resale (goods distribution). This covers food-waste processors, refurbished and new network and server hardware (inherited from the 2023–2025 absorption of IT-infrastructure reseller Ainsys INC), and API sales. Service income such as IT maintenance, rental and data erasure from the Ainsys book, and game-publishing revenue appear to be minor. No subscription or licensing model has been disclosed.
Value-chain position: a downstream distributor and reseller with low gross margins. Google Finance quarterly data show cost of goods sold absorbing 74%–89% of revenue between Q2 FY2025 and Q1 FY2026, implying gross margins of roughly 11%–26%. The original Pharmswell/Co-Biotech business was an upstream API manufacturer with BGMP and KGSP-certified facilities (Incruit company profile). Whether meaningful in-house API manufacturing remains is not publicly disclosed.
Customer types: B2B in IT hardware (telecoms, cloud managed-service providers, system integrators, government agencies and global third-party-maintenance firms, per the 2023 Ainsys description). B2B2C and B2C in food-waste processors (construction companies, retail, schools, restaurants and large marts were named as target channels in 2022). B2B in APIs (domestic finished-dose pharmaceutical makers).
End-markets: Korean domestic markets only. ValueLine shows no export revenue line.
Business-model evolution (strategic "identity" by controlling shareholder)
| Period | Controlling shareholder | Corporate name | Business narrative |
|---|---|---|---|
| 2008–2019 | Founder-era management, later Daol Pharmaceutical and related party | Pharmswell Bio | Synthetic and fermentation API manufacturer; 2017–2019 push into in-vitro diagnostics via affiliate Cube Bio |
| 2019–2021 | Cube Partners No.1 Partnership (큐브파트너스1호조합) | Cube&Company | API plus diagnostics (purine-metabolite analysis kit via Cube Bio) |
| Jul 2021–Aug 2022 | Hanchang Corp. (㈜한창, KOSPI) | Hanju Chemical & Holdings → Hanchang Biotech | API, 40% stake in fire-suppression maker Hanju Chemical, real-estate PM, online commerce, food-waste processor distribution, "metaverse/NFT" vision |
| Aug 2022–2023 | Jeonheung C&C (전흥씨엔씨; chairman Lee Yong-heung of World One Hi-Tech) | Exergy21 | Air-source heat-pump distribution, smart-farm energy efficiency, IT infrastructure (Ainsys), UAV and anti-drone investments |
| Late 2023–Nov 2025 | PNS Industry Fund (contributors incl. Multo, Sight Planners, PNS The Curtain Wall) | The Technology | Distribution (food-waste processors), network equipment, mobile games |
| Nov 2025–present | PNS Industry Fund, now led by DB Investment and Fastround | The Technology | Delisting litigation; investment in Xecure Hitron convertible bonds |
Sources: Dealsite 14 Nov 2024; Asia Economy 15 Nov 2021, 8 Aug 2022; Energy Economic News 25 Mar 2024; Dealsite 5 Nov 2025.
Strategy
Stated strategy (paraphrased from the latest periodic report summary)
Management's stated strategy is to improve revenue and create new profit sources through diversification into four lines: distribution (food-waste processors as an ESG play), network equipment, mobile games and residual pharmaceuticals. The goal is to keep expanding the portfolio (ValueLine summary of the latest report). After the delisting decision, management's public priority was restoring listing eligibility by lifting stand-alone revenue, with profitability to be "addressed gradually" (company official, paraphrased; Dealsite 7 Jul 2025).
No investor day has been held and no medium-term targets have been published.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status / outcome | Source |
|---|---|---|---|---|
| Capital reduction (first attempt) | Nov 2024 | 3-for-1 share consolidation to eliminate the accumulated deficit | Failed: EGM lacked quorum | Dealsite 14 Nov 2024 |
| Capital reduction (second attempt) | Dec 2024 – Aug 2025 | 10-for-1 consolidation proposed; a reduction became effective in Aug 2025 (largest holder's stake fell by a factor of 6) | Executed (final ratio as implemented not confirmed) | Dealsite 4 Dec 2024; Digital Today 3 Sep 2025 |
| BW issuance | 2,024 | KRW 12.5bn bond with warrants | Completion not publicly disclosed | Dealsite 14 Nov 2024 |
| Syswork acquisition | 2024 – Jul 2025 | Joined the ReValued Work consortium with the then-largest shareholder Multo to acquire Syswork, then in court rehabilitation | Terminated Jul 2025 for lack of funds and limited effect on stand-alone revenue | Dealsite 7 Mar 2025, 7 Jul 2025 |
| Ainsys absorption | Decided Jul 2023; amended Mar 2025 | Bring IT-hardware revenue into the stand-alone accounts | Completed 2025 | KIND 31 Mar 2025; Dealsite 7 Jul 2025 |
| Delisting litigation | Sep 2025 – Jul 2026 | Injunction against the KOSDAQ delisting decision | Dismissed 28 Jul 2026 | ChickStock (DART) |
| Xecure Hitron investment | Oct–Nov 2025 | KRW 4bn purchase of Xecure Hitron CBs, joint participation in its KRW 8bn rights issue and joint purchase of a 6.55% stake, alongside Sonokong | Completion not publicly disclosed; strategic rationale questioned by the press | Dealsite 5 Nov 2025; Hankyung 14 Nov 2025 |
| Further share consolidation | 2,026 | Share count cut to about 4.14M; trading halt extended pending new-share listing | Executed | Datatooza 9 Apr 2026; ValueLine |
| K-OTC trading | Sep 2026 | Designated to the Delisted Company Section (provides liquidity, not a relisting path) | Trading from 30 Sep 2026; maximum 6 months | SBS Biz 28 Sep 2026 |
ESG, cost programmes and guidance
ESG: the food-waste processor business and the Exergy heat pump were positioned as ESG and carbon-reduction initiatives. No emissions targets were set.
Cost programmes: none with quantified targets disclosed.
Guidance: none. Historical "guidance" consisted of executive statements, none of which materialised:
-
2021: return to operating profit "next year" and revenue growth of "several tens of times" (Asia Economy 23 Nov 2021).
-
2022: continue profitability (Asia Economy 12 May 2022).
Products & Services
The catalogue below lists every product line identified in public sources. Fields not disclosed are marked as such.
Distribution segment
| Product / line | Description | Key capabilities (as described by company) | Target customer | Launch / latest year | Pricing model |
|---|---|---|---|---|---|
| MUMS (멈스) bio food-waste processor | Microbial-decomposition food-waste disposer distributed under a general-distributorship right | Biological (microbe-based) decomposition of household and commercial food waste | Housing developers, retail, schools, restaurants, large marts | Distribution from late 2021/2022 | Not publicly disclosed (product resale) |
| Other traded goods | General distribution | — | — | 2021 onward | Resale |
| Online commerce (legacy, 2021) | Influencer × apparel/cosmetics brand collaborations | New-media commerce | Consumers | Announced Nov 2021 | — |
Source: Asia Economy 12 May 2022, 15 Nov 2021.
Network Equipment segment (ex-Ainsys INC)
| Product / service | Description | Capabilities | Customers (as of 2023) | Year | Pricing |
|---|---|---|---|---|---|
| IT infrastructure hardware supply | Servers, storage, network equipment for IT build-outs | New and refurbished (recycled) enterprise hardware | Government agencies, KT, Megazone Cloud, Naver Systems, Namutech | Ainsys founded 2011 | Resale |
| Equipment rental | Short/long-term rental of IT hardware | — | As above | — | Rental fees (not disclosed) |
| Data erasure | Certified data deletion on decommissioned equipment | — | As above | — | — |
| Equipment relocation and integrated maintenance | Data-centre moves; third-party maintenance (TPM) | Company said Ainsys was the only Korean firm listed in a Gartner TPM market guide; member of the Service Industry Association | Park Place Technologies, Nordic Computer, Exeo Global, domestic clients | — | Service contracts (not disclosed) |
| "AICE security" / AI network detection and response (planned) | Unsupervised-learning AI security engine | Network detection and response | — | Planned 2023 | — |
Source: Asia Economy 28 Jul 2023; Financial News 3 Apr 2023; TheVC.
Games segment
| Product / service | Description | Partner | Year | Pricing |
|---|---|---|---|---|
| Mobile-game publishing | Launch and direct publishing of mobile titles through alliances | Pangsky (FY2023 revenue KRW 20.8bn, operating profit KRW 1.1bn, per press) | 2024 onward | Not disclosed; title names not publicly disclosed |
Source: Energy Economic News 25 Mar 2024; ValueLine summary.
Other segment
| Product / line | Description | Capabilities | Target customer | Year | Pricing |
|---|---|---|---|---|---|
| Generic APIs (synthetic) | Development, manufacture and distribution of generic APIs at BGMP/KGSP facilities | Synthesis know-how and patents (Pharmswell); individual molecules not publicly disclosed | Korean finished-dose drug makers | Since 1999/2008 | — |
| Fermentation-derived APIs (legacy Co-Biotech) | Fermentation technology and production equipment | Fermentation | Pharma companies | Since 1987 | — |
| Avian-influenza treatment process (historical) | Manufacturing process completed in 2005; joint R&D with Daehan New Pharm to 2010 | Process chemistry | — | 2,005 | — |
| Microbial bio products | Microbe-based bio products named as a future revenue driver | — | — | Announced Nov 2021 | — |
| Exergy21 air-source heat pump | Large-capacity air-heat heat-pump heating/cooling/hot-water system developed by former co-CEO Lee Yong-heung | No fossil fuel. Company claimed 54%–85% heating/cooling cost savings; installed at Samsung Omni Tower (2005), KT labs and IDCs, a 5,000-pyeong mushroom farm in Gimje, and herb and paprika farms | Smart farms, large commercial buildings, data centres | Distribution from Oct 2022 | — |
| Purine-metabolite analysis kit (Cube Bio, affiliate) | In-vitro diagnostic kit; production plant planned in Wonju | Purine metabolomics | Clinics, screening | Planned 2018–2019 | — |
| Real-estate PM (legacy) | Project management for redevelopment from permitting to completion | Leveraged Hanchang's experience | Developers | 2,021 | Contract fees (KRW 0.9bn and 1.4bn contracts) |
| Anti-drone (Exergy Solutions) | Counter-UAV business | — | — | 2,023 | — |
Sources: Medical Times 8 May 2008; Incruit; Financial News, MT and NBN 28 Oct 2022; Etoday 4 Jun 2018; Asia Economy 15 Nov 2021, 28 Jul 2023.
Financial Narrative
Important caveats
-
Falsified revenue. The FSC found that the company booked fictitious goods sales and cost of sales of KRW 2,374M in FY2021 and KRW 2,165M in FY2022. The transactions had no commercial substance or collectability, and the company obstructed its external audit (Metro Seoul 17 Jun 2026; Policy Briefing summary). Whether published FY2021–FY2022 figures have been restated is not publicly disclosed.
-
Inconsistent comparatives. The FY2023 results release stated revenue growth of +330.2%, operating-loss growth of +216.6% and net-loss growth of +680% (Edaily, Mar 2024). These ratios do not reconcile with the FY2022 figures originally published (revenue KRW 3,874M; operating loss KRW 3,887M; net profit KRW 4,730M; Edaily, Mar 2023). This implies the FY2022 comparatives were restated or reclassified, possibly for discontinued operations linked to the Hanju Chemical disposal. The restated FY2022 figures are not publicly disclosed.
-
FY2021 revenue is derived. It is back-calculated from the reported −56.21% FY2022 decline: 3,874 / (1 − 0.5621) ≈ 8,847.
-
Balance-sheet, cash-flow, EPS and ratio data beyond those listed are not publicly disclosed in accessible sources.
Income statement
Sources: FY2022 — Edaily (Mar 2023). FY2023 — Edaily (Mar 2024). FY2024 — Digital Today 3 Sep 2025 and 25 Sep 2025. FY2025 — Digital Today 28 Jul 2026. FY2021 — derived. Dividends: no dividend was reported in any source reviewed, and accumulated deficits would legally prevent one; recorded as zero.
Earlier reference points:
FY2020 (Cube&Company): revenue ≈KRW 5,200M and operating loss ≈KRW 3,600M, as cited by the CEO at the Nov 2021 EGM (Asia Economy 23 Nov 2021).
FY2007 (Pharmswell stand-alone): revenue KRW 24,100M, operating profit KRW 3,200M (Medical Times 8 May 2008).
Growth
- FY2023 growth is computed against the originally published FY2022 revenue; the company reported +330.2%.
Revenue CAGR FY2022–FY2025: about +48.2% a year on reported figures. This is inflated by the low, partly fabricated FY2022 base.
Revenue CAGR FY2021–FY2025: about +9.2% a year (derived FY2021 base).
- On a basis that excludes fabricated sales, the FY2021 to FY2025 change is roughly +18% a year. This is an analyst derivation and assumes the reported FY2021 figure was not already restated.
Balance sheet
Sources: Digital Today 3 Sep 2025 (FY2024); Digital Today 28 Jul 2026 (FY2025).
Additional disclosed balance-sheet data points:
Cash and short-term financial instruments: KRW 13.3bn at 31 Mar 2023 (Dealsite 2 Aug 2023).
Unredeemed CBs: KRW 26.4bn across series 17, 18, 20 and 21 at Aug 2023 (Dealsite 2 Aug 2023).
Hanju Chemical sale receivable: KRW 23bn balance, deferred to 31 Jan 2024 (Dealsite 2 Aug 2023). Collection status is not publicly disclosed.
BW issuance decided: KRW 12.5bn bond with warrants approved in 2024 (Dealsite 14 Nov 2024). Completion status is not publicly disclosed.
Implied equity, end-2019: ≈KRW 26bn (derived: a KRW 2.71bn CB resale equalled 10.42% of equity; Etoday 26 Jun 2020).
Cash flow
ValueLine Korea publishes a cash-flow line, but the values extracted were not interpretable with confidence, so they are excluded under the no-fabrication rule.
Ratios (computed on year-end balances where available)
Aggregator cross-checks: ValueLine shows trailing ROE of −76.49% at the Q1 FY2026 update; StockHub shows −80.17%.
Quarterly and trailing data (aggregators)
Source: Google Finance (S&P data). These quarterly operating figures do not fully reconcile with the reported FY2025 operating loss of KRW 3.2bn. Q2–Q4 alone sum to −KRW 5.0bn, which would imply a positive Q1 FY2025. Treat them as indicative only.
Source: ValueLine Korea (consolidated, Q1 FY2026 update).
Commentary on trends, inflections and drivers
Structural decline of the core. In 2007, Pharmswell alone generated KRW 24.1bn of revenue at a 13% operating margin. By FY2020 the renamed Cube&Company reported about KRW 5.2bn of revenue and a KRW 3.6bn operating loss. The API franchise appears to have eroded through the late 2010s while management attention and capital went to diagnostics (Cube Bio) and the Wonju relocation. Every subsequent "new business" was layered on a shrinking core.
FY2021–FY2022: revenue of questionable quality. Revenue in these years mixed real but small new lines (PM fees, early MUMS distribution) with fictitious goods-trading sales later identified by the FSC. Fabricated sales were about 27% of derived FY2021 revenue and 56% of reported FY2022 revenue. FY2022's reported net profit of KRW 4.7bn was not operational: it came from the Hanju Chemical stake (equity income, then a disposal for KRW 25bn), while operating losses persisted at about KRW 3.9bn.
FY2023: inflection in scale, not economics. Revenue rose to KRW 16.8bn, mainly by consolidating the Ainsys IT-hardware business (about KRW 19.6bn revenue on its own in FY2022). Operating loss widened to KRW 16.0bn and net loss to KRW 26.2bn. Management blamed rate rises and inflation (Edaily, Mar 2024). In practice, the loss reflects low-margin hardware resale, heavy SG&A, and probable write-downs of the investment portfolio (Katus, CB-funded ventures) and of the heat-pump business. The breakdown is not publicly disclosed.
FY2024: contraction. Consolidated revenue fell 38% to KRW 10.4bn. Stand-alone revenue fell 53% to KRW 2.3bn, below the KOSDAQ KRW 3bn threshold, which triggered the listing review. Operating loss narrowed to KRW 7.2bn but net loss stayed high at KRW 18.4bn. Equity of KRW 30.7bn masked a large accumulated deficit, which the failed and then re-attempted capital reductions were designed to eliminate.
FY2025: smaller losses, shrinking balance sheet. Revenue recovered to KRW 12.6bn as the Ainsys absorption moved hardware sales into the stand-alone entity, and operating loss narrowed to KRW 3.2bn. Net loss of KRW 14.3bn was again far larger than the operating loss, pointing to continued financial-asset write-downs or valuation losses. Total assets more than halved from KRW 43.3bn to KRW 20.0bn and equity fell from KRW 30.7bn to KRW 16.0bn in one year: a rapid consumption of the capital base.
Q1 FY2026. Revenue of about KRW 4.4bn was the best quarter in the aggregator series, but the company still lost about KRW 0.6bn at the operating line on gross margins of roughly 15%. On TTM data, net losses are narrowing (−KRW 11.75bn at March 2026) but remain about 80% of revenue.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Products / services |
|---|---|---|
Distribution (유통사업부문) | Food-waste processing business and general goods distribution | Food-waste processors (the MUMS brand was distributed under exclusive rights from 2022) and other traded goods |
Network Equipment (네트워크장비사업부문) | IT-infrastructure hardware business absorbed from Ainsys INC | Servers, storage and network equipment; historically also rental, data erasure, relocation and third-party maintenance |
Games (게임사업부문) | Mobile-game publishing | Mobile-game launches and publishing under alliances (Pangsky CB investment in 2024) |
Other (기타사업부문) | Legacy and residual activities | Pharmaceuticals/APIs, the Exergy air-source heat pump, other |
Segment revenue (KRW Mn)
| Segment revenue (KRW Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue | 16,762 | 10,400 | 12,600 |
Segment operating profit (KRW Mn)
| Segment operating profit (KRW Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated operating profit | -16,006 | -7,200 | -3,200 |
Group Entities
| Entity | Relationship | Business | Status | Source |
|---|---|---|---|---|
The Tech D&R (㈜더테크디엔알) | Consolidated subsidiary | — | Active per Q3 FY2025 report | KIND Q3 FY2025 |
Exergy Solutions (엑서지솔루션스) | Subsidiary | Anti-drone business | Status not publicly disclosed | Asia Economy 28 Jul 2023 |
Ainsys INC (아인시스아이엔씨) | Former 100% subsidiary, absorbed | IT infrastructure hardware, TPM | Absorbed; recorded as closed Jun 2025 | KIND 31 Mar 2025; TheVC |
Hanju Chemical (한주케미칼) | Former 40% associate | Gas-type fire suppression | Sold back to Hanchang (KRW 25bn) | Dealsite 2 Aug 2023 |
Cube Bio (큐브바이오) | Former affiliate | In-vitro diagnostics (purine-metabolite analysis kit) | Relationship status not publicly disclosed | Etoday 2018–2019 |
Katus (카투스) | Equity investee (KRW 6bn, May 2023) | UAV | Status not publicly disclosed | Dealsite 2 Aug 2023 |
Pangsky (팡스카이) | CB investee (2024) | PC/mobile game publishing | Status not publicly disclosed | Energy Economic News 25 Mar 2024 |
“—” = not publicly disclosed.
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 8,847 | 3,874 | 16,762 | 10,400 | 12,600 |
Of which fabricated revenue found by FSC (KRW Mn) | 2,374 | 2,165 | — | — | — |
Revenue excl. fabricated sales, analyst-derived (KRW Mn) | 6,473 | 1,709 | 16,762 | 10,400 | 12,600 |
Operating income (KRW Mn) | — | -3,887 | -16,006 | -7,200 | -3,200 |
Net income (KRW Mn) | — | 4,730 | -26,169 | -18,400 | -14,300 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating margin (%) | -100.3 | -95.5 | -69.2 | -25.4 |
Net margin (%) | 122.1 | -156.1 | -176.9 | -113.5 |
Margin Analysis (%) — Revenue YoY growth
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue YoY growth (%) | -56.2 | 332.7 | -38.0 | 21.2 |
Balance Sheet
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (KRW Mn) | 43,300 | 20,000 |
Total liabilities (KRW Mn) | 12,600 | 3,900 |
Total equity (KRW Mn) | 30,700 | 16,000 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%) | -59.9 | -89.4 |
ROA (%) | -42.5 | -71.5 |
Liabilities to equity (%) | 41.0 | 24.4 |
Asset turnover (x) | 0.24 | 0.63 |
Equity to assets (%) | 70.9 | 80.0 |
Income Statement (Quarterly)
| Metric (KRW Mn) | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 |
|---|---|---|---|---|
Revenue | 2,440 | 1,750 | 6,380 | 4,370 |
Cost of goods sold | 1,620 | 1,290 | 5,690 | 3,710 |
SG&A | 1,350 | 995 | 873 | 1,090 |
Operating income | -3,930 | -873 | -207 | -593 |
Pre-tax income incl. unusual items | -5,210 | -785 | -5,900 | 338 |
Income Statement (KRW)
| Trailing-12-month metric (KRW 100M) | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
TTM revenue | 99.2 | 98.9 | 87.1 | 125.7 | 149.6 |
TTM net income | -170.7 | -198.0 | -152.9 | -143.0 | -117.5 |
Region revenue (KRW Mn)
| Region revenue (KRW Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
South Korea | 16,762 | 10,400 | 12,600 |
Capital Markets
| Item | Detail | Source |
|---|---|---|
KOSDAQ listing | Oct 2001 – 10 Aug 2026 | Findata; Digital Today |
Current venue | K-OTC Delisted Company Section from 30 Sep 2026, for up to 6 months; reference price KRW 103; daily limit ±30% | SBS Biz; Bizwatch 28 Sep 2026 |
Par value | KRW 500 | Dealsite 14 Nov 2024 |
Share Price History
| Date | Price (KRW) | Context | Source |
|---|---|---|---|
9 Aug 2022 | 5,280 | Intraday high after the change-of-control news | Dealsite 2 Aug 2023 |
27 Jul 2023 | 535 | Intraday low, down about 90% from the peak | Dealsite 2 Aug 2023 |
1 Aug 2023 | 701 | Close | Dealsite 2 Aug 2023 |
13 Nov 2024 | 334 | Close, 33% below par | Dealsite 14 Nov 2024 |
2025 (suspension) | 380 | Last price before the trading halt (post-Aug 2025 reduction basis) | Digital Today 3 Sep and 25 Sep 2025 |
Jul 2026 (pre-liquidation, consolidated basis) | 1,140 | 380 adjusted for the 2026 3-for-1 consolidation (derived from StockHub 52-week high) | StockHub; analyst derivation |
30 Jul 2026 | 228 | First liquidation-trading day, −80% | ValueLine |
7 Aug 2026 | 171 | Liquidation trading (intraday, −18.57%) | StockHub |
30 Sep 2026 | 103 | K-OTC reference price | Bizwatch 28 Sep 2026 |
Share Price & Returns
| Period | Return | Basis | Source |
|---|---|---|---|
1-year (to May 2025) | -85.5% | Simply Wall St | Simply Wall St |
1-year (to 30 Sep 2026) | about -91% (1,140 adjusted → 103) | Analyst derivation | Derived |
3-year (Aug 2023 → Sep 2026) | below -99% after cumulative consolidations | Analyst derivation; exact figure depends on consolidation ratios not fully confirmed | Derived |
5-year | below -99% | As above | Derived |
Market Valuation
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Market cap (KRW Mn) | 11,900 | 4,700 | 426 |
Valuation Snapshot
| Multiple | Value | Source |
|---|---|---|
P/E | Negative (−0.08x on ValueLine, 30 Jul 2026) | ValueLine |
P/B | 0.06x (ValueLine, 30 Jul 2026); 0.03x (StockHub, 7 Aug 2026) | ValueLine; StockHub |
EV/EBITDA | Not meaningful (negative EBITDA; EBITDA not disclosed) | — |
EV/Sales | About 0.03x (derived from a KRW 0.43bn market cap on FY2025 revenue of KRW 12.6bn, before net cash/debt, which is not disclosed) | Derived |
Peer multiples | Not compiled | — |
Analyst Conclusions
Management guidance and consensus
There is no management guidance and no consensus. The only forward-looking statements on record are the 2021–2022 promises of turnaround, which did not materialise, and the 2025 commitment to expand stand-alone revenue to preserve the listing, which failed.
Bull case
-
Operating losses are shrinking. Operating loss narrowed from −KRW 16.0bn (FY2023) to −KRW 3.2bn (FY2025), and Q1 FY2026 revenue (about KRW 4.4bn) annualises to roughly KRW 17bn. If the hardware and distribution lines hold 15%–20% gross margins and overhead is cut, operating breakeven is conceivable.
-
The market is pricing the equity near zero against KRW 16.0bn of book equity. At the KRW 103 K-OTC reference price (P/B well below 0.1x), any credible recapitalisation, asset sale or realisation of the Xecure Hitron or other investments could re-rate the shares.
-
New controllers may have an agenda for the shell. The November 2025 shift to DB Investment and Fastround and the Xecure Hitron transactions indicate active capital deployment. A recapitalisation or K-OTC "registered" status could provide an orderly path for remaining holders.
Bear case
-
The listing is gone and the funding model is broken. Since 2019 the company has financed losses mainly through CBs, BWs and third-party rights issues sold into a KOSDAQ-listed stock. As a delisted K-OTC name with a six-month designation window, that channel is effectively closed while losses continue (FY2025 net loss KRW 14.3bn).
-
Book value is eroding faster than it can be defended. Equity fell 48% in FY2025 alone. Net losses repeatedly exceed operating losses, consistent with write-downs of investments, so the remaining KRW 16bn may be similarly impaired.
-
Legal and governance overhang. Prosecutorial referral, a three-year designated auditor, a confirmed history of fabricated revenue and audit obstruction, and six or more control changes make outside capital and customer trust hard to attract. Any further adverse audit opinion would compound this.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | Why it matters |
|---|---|---|
| K-OTC Delisted Company Section expiry | About 6 months after 30 Sep 2026 (≈ end-Mar 2027) | Decides whether organised trading continues |
| KOFIA decision on re-designation to the K-OTC registered/designated sections | At expiry | Ongoing liquidity |
| FY2026 annual report and audit opinion (designated auditor) | ~Mar 2027 | Going-concern assessment; test of the new audit regime |
| Prosecutorial outcome on the SFC referral | Not scheduled | Potential criminal liability; damages claims |
| Status of Xecure Hitron CB, rights-issue and block positions | Pending disclosure | Asset value or loss |
| Further capital raising or control changes by DB Investment / Fastround | Unknown | Recapitalisation versus wind-down |
| Quarterly gross margin and operating loss trend | Quarterly | Whether the operating improvement is sustainable |
| Minority-shareholder litigation | Unknown | Contingent liabilities |
Analyst verdict
Cube&Company — today The Technology Co., Ltd. — is a case study of how a small but once-genuine Korean pharmaceutical-ingredients manufacturer can be turned into a vehicle for successive capital-markets strategies. In 2007 its predecessor earned a 13% operating margin on KRW 24bn of API revenue. By 2020 the core had shrunk to about KRW 5bn of loss-making sales.
Each controller from 2019 onward introduced a new narrative, a new name and new mezzanine financing:
-
diagnostics;
-
a fire-suppression holding;
-
real-estate project management;
-
heat pumps and smart farms;
-
second-hand servers;
-
mobile games;
-
anti-drone technology.
None of these produced durable, profitable scale. Regulators have since established that FY2021–FY2022 revenue was partly fictitious, and that the company obstructed its auditor.
The FY2025 numbers show some operational stabilisation: consolidated revenue of KRW 12.6bn and an operating loss narrowed to KRW 3.2bn. But they are undercut by a KRW 14.3bn net loss and a halving of equity within one year. More fundamentally, the delisting on 10 August 2026 removed the listed currency on which the entire post-2019 model depended.
The K-OTC designation provides a temporary exit window for minority holders; it does not resolve the underlying problems. The KRW 103 reference price, which values the company at well under 0.1x book, is the market's verdict that reported equity is not recoverable by outside shareholders.
For institutional purposes the company is uninvestable. The legal, governance and going-concern risks are not compensated by any identifiable franchise value. The residual analytical interest lies in three questions: whether the new controllers, DB Investment and Fastround, recapitalise or extract the remaining assets; what the designated auditor concludes on FY2026; and how the prosecutorial referral resolves. Counterparties extending trade credit or entering distribution agreements should apply heightened due diligence and secure payment terms.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Age |
|---|---|---|---|---|
Park Sung-min (박성민) | CEO | In office by Sep 2026; start date not publicly disclosed | — | — |
Jeon Young-mo (전영모) | CEO (appointed 25 Sep 2025); current status not confirmed | From Sep 2025 | Director, Stefano Equity (unlisted), Jan 2022 – Jun 2025 | Born 4 Jul 1968 |
“—” = not publicly disclosed.
Board & Management Changes
| Period | CEO / key director | Context | Source |
|---|---|---|---|
| 2008 | Kwon Young-jin (Pharmswell CEO) | Became CEO of the merged Pharmswell Bio; Simply Wall St still lists him (stale data) | Medical Times 8 May 2008; Simply Wall St |
| 2018 | Choo Yeon-woo | CEO during the Wonju relocation and Cube Bio build-out | Etoday 4 Jun 2018 |
to Oct 2019 | Park Kang-kyu | Resigned for personal reasons | Hankyung 24 Oct 2019 |
Oct 2019 | Jung Jae-heon | Appointed at the Cube&Company rename | Hankyung / Newspim 24 Oct 2019 |
2020–2023 | Lee Ji-sun (inside director, management support) | Previously at Namsung, Pharmswell Bio/Cube Bio, Hansol Secure; term Mar 2020 – Mar 2023 | Findata DART extract |
| 2021 | Choi Seung-hwan | CEO under Hanchang ownership | Asia Economy 23 Nov 2021 |
Sep 2022 | Lee Yong-heung (co-CEO) | Chairman of World One Hi-Tech and Jeonheung C&C; developer of the Exergy21 heat pump | Financial News 28 Oct 2022 |
Mar 2023 | Choi Chang-geun (inside director; CEO of Ainsys INC); Hong Soon-ho (inside director; CPA, Shinhan Accounting) | Appointed at the FY2022 AGM | Financial News 3 Apr 2023 |
to Sep 2025 | Oh Jong-bong | Resigned as CEO for personal reasons | Digital Today 25 Sep 2025 |
Sep 2025 | Jeon Young-mo | Appointed CEO | Digital Today 25 Sep 2025 |
by Sep 2026 | Park Sung-min | CEO at the time of the K-OTC designation | Sateconomy 28 Sep 2026 |
Major Shareholders
| Holder | Shares | Stake (%) | Date | Source |
|---|---|---|---|---|
PNS Industry Fund (피엔에스인더스트리펀드) and related parties | 1,666,666 (post Aug 2025 reduction) | 13.42 | 3 Sep 2025 | Digital Today 3 Sep 2025 |
Same holder, prior report | 10,000,000 | 14.47 | 29 Dec 2023 | Digital Today 3 Sep 2025 |
Same holder, implied after the 2026 consolidation | ≈555,555 (derived assuming a 3-for-1 consolidation) | ≈13.4 (derived) | 2026 | Analyst derivation from ValueLine share count |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning |
|---|---|---|---|
Distribution (food-waste processors) | Smartcara (스마트카라) | Specialist appliance brand | Established brand vs. the company's reseller role |
Distribution | SK Magic (SK매직) | Large home-appliance company | Scale, rental model and channel reach far exceed the company |
Distribution | Cuckoo (쿠쿠) | Large appliance group | Brand and distribution advantages |
Network equipment / IT hardware and TPM | Park Place Technologies | Global TPM leader (also a historical Ainsys customer) | Global scale; partner-competitor |
Network equipment | Syswork (시스웍) | Korean network-equipment firm (target abandoned in 2025) | Comparable domestic niche |
Network equipment | Insung Information (인성정보) | Network-infrastructure distributor | Larger domestic distributor |
Games | Pangsky (팡스카이) | Game publisher (investee/partner) | Larger than the company's games unit (FY2023 revenue KRW 20.8bn) |
APIs (Other) | Kyongbo Pharm (경보제약) | Korean API maker | Larger, focused API producer |
APIs | Kukjeon Pharmaceutical (국전약품) | Korean API maker | Focused competitor |
APIs | Estech Pharma (에스텍파마) | Korean API maker | Focused competitor |
APIs | Hwail Pharm (화일약품) | Korean API maker / distributor | Focused competitor |
Competitor Detail
| Metric | The Technology FY2025 |
|---|---|
Revenue (KRW Mn) | 12,600 |
Revenue growth (%) | 21.2 |
Operating margin (%) | -25.4 |



